title: Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia.
abstract: BACKGROUND
  The aim of this study was to determine whether antibiotic prophylaxis during periods of neutropenia reduced streptococcal (S. viridans) sepsis and overall bacterial sepsis.
  
  
  METHODS
  The authors reviewed outcomes of 78 evaluable patients who were consecutively treated for acute myeloid leukemia (AML) from October 2002 through January 2007. Several successive prophylactic antibiotic regimens were used. All patients received antifungal prophylaxis with oral voriconazole.
  
  
  RESULTS
  Oral cephalosporins did not significantly reduce the odds of bacterial sepsis (P = .81) or streptococcal (S. viridans) sepsis (P = .90) relative to no prophylaxis. Intravenous (iv) cefepime completely prevented streptococcal (S. viridans) sepsis and reduced the odds of bacterial sepsis 91% (P < .0001) relative to no prophylaxis, but resistant gram-negative bacteria emerged in 2 patients. Vancomycin with oral ciprofloxacin or a cephalosporin reduced the odds of bacterial sepsis by 93% (P < .0001) and streptococcal (S. viridans) sepsis by 99% (P < .0001). The fungal infection rate did not differ significantly between patients who did and did not receive antibiotic prophylaxis (1.0 per 1000 patient-days for both groups). The observed reduction in average hospital days per chemotherapy course for patients given vancomycin regimens or cefepime was 5.7 (P < .0001) and 4.1 (P = .0039) days, respectively. No reduction was observed with oral cephalosporins (P = .10). Furthermore, vancomycin regimens or cefepime were associated with a 20% reduction in healthcare charges (P = .0015) relative to using no antibiotics. One patient, who was on oral cefuroxime alone, died of septicemia.
  
  
  CONCLUSIONS
  Prophylaxis with intravenous cefepime or a vancomycin regimen, and voriconazole, reduced morbidity in children with AML, and resulted in dramatic decreases in the incidence of septicemia and hospitalization days.
authors.affiliation: Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA.
authors.forename: Beth
authors.initials: B
authors.lastname: Kurt
authors.forename: Patricia
authors.initials: P
authors.lastname: Flynn
authors.forename: Jerry L
authors.initials: JL
authors.lastname: Shenep
authors.forename: Stanley
authors.initials: S
authors.lastname: Pounds
authors.forename: Shelly
authors.initials: S
authors.lastname: Lensing
authors.forename: Raul C
authors.initials: RC
authors.lastname: Ribeiro
authors.forename: Ching-Hon
authors.initials: CH
authors.lastname: Pui
authors.forename: Bassem I
authors.initials: BI
authors.lastname: Razzouk
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Rubnitz
mesh_terms: D019072:Antibiotic Prophylaxis; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D018805:Sepsis / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000970:Antineoplastic Agents